CN113416122B

CN113416122B - Extraction and separation method of aryl compound in purslane and application thereof

Info

Publication number: CN113416122B
Application number: CN202110642166.3A
Authority: CN
Inventors: 英锡相; 郭胜男; 何凡
Original assignee: Liaoning University of Traditional Chinese Medicine
Current assignee: Liaoning University of Traditional Chinese Medicine
Priority date: 2021-06-09
Filing date: 2021-06-09
Publication date: 2022-05-06
Anticipated expiration: 2041-06-09
Also published as: CN113416122A

Abstract

The invention relates to the field of extraction and separation of traditional Chinese medicines, in particular to a novel compound extracted, separated and identified from purslane and an extraction and separation method thereof. The novel compound has a molecular formula of C₄₄H₄₂O and is named according to the structure ((1)S,1'S,1''S,1'''S) - (oxybis (bezene-2, 1,3-triyl)) tetrakis (ethane-1,1-diyl)) tetrabenzene. Also provides an extraction and separation method of the new compound, which sequentially adopts 40-60% ethanol reflux extraction, silica gel column chromatography, ODS medium-pressure column, Sephadex LH-20 purification and HPLC separation preparation. The structure of the compound is determined to be a new compound by adopting a method of ultraviolet, infrared, mass spectrum, hydrogen spectrum, carbon spectrum and two-dimensional nuclear magnetic spectrum analysis. The compound has anti-inflammatory and anti-tumor effects, and the novel compound and the salt or the derivative thereof can be used as a lead for synthesizing other compounds and raw materials for developing new drugs and researching pharmacological activity and used for preparing anti-inflammatory and anti-tumor drugs.

Description

Extraction and separation method of aryl compound in purslane and application thereof

Technical Field

The invention relates to the field of extraction and separation of traditional Chinese medicines, in particular to a novel compound extracted, separated and identified from a purslane medicinal material and an extraction and separation method thereof.

Background

Purslane (herba Portulacae)Portulaca oleraceaL.), herba Portulacae and herba Portulacae, which are plants of Portulacaceae. Purslane is fertile and fertile in soil, drought and waterlogging resistant, strong in vitality, wide in distribution and rich in resources. The purslane can be used as a medicine and can be eaten, and is one of wild plants which are determined by the Ministry of health and have homology of medicine and food. The 2020 edition is recorded in pharmacopoeia of people's republic of China to take dry aerial parts of purslane as medicine, has the effects of clearing away heat and toxic materials, cooling blood and stopping bleeding, and stopping dysentery, and can be used for treating heat-toxin bloody dysentery, carbuncle, furuncle, eczema, erysipelas, snake and insect bite, hematochezia, hemorrhoidal bleeding, metrorrhagia and metrostaxis and the like.

Modern pharmacological studies show that the purslane has the effects of resisting inflammation, oxidation and tumors, resisting atherosclerosis, reducing blood fat, reducing blood sugar, relaxing or exciting smooth muscles, enhancing immunity and the like. Research shows that various chemical components contained in purslane are closely related to various pharmacological effects of purslane, and the main chemical components of the purslane comprise: alkaloids, flavonoids, terpenoids, coumarins, organic acids, volatile oil, polysaccharides, amino acids, various pigments and minerals.

Most of the chemical components separated from purslane are known and have low structural novelty, so the development and separation of new compounds in purslane are urgently needed.

Disclosure of Invention

In order to solve the problems, the invention provides a novel compound extracted from purslane, and researches show that the novel compound has anti-inflammatory and anti-tumor effects, and simultaneously provides a simple, convenient, rapid, environment-friendly and high-purity extraction and separation method for the compound.

In order to achieve the above object, the present invention provides the following technical solutions.

The invention provides an aryl compound separated from purslane medicinal material, which is characterized in that the molecular formula of the compound is C₄₄H₄₂O, namely ((1)S,1'S,1''S,1'''S) - (oxybis (bezene-2, 1,3-triyl)) tetrakis (ethane-1,1-diyl)) tetrabenzene having the chemical formula:

。

the invention also provides an extraction and separation method of the aryl compound separated from the purslane medicinal material, which is characterized by comprising the following specific steps:

step 1: reflux-extracting herba Portulacae dry medicinal materials with 50% ethanol, filtering extractive solution, mixing filtrates, directly heating and concentrating, and cooling to room temperature to obtain medicinal liquid;

step 2: putting the concentrated solution obtained in the step 1 on a silica gel column, eluting with ethyl acetate, and recovering ethyl acetate under reduced pressure to obtain an extract to obtain an ethyl acetate extract;

and step 3: separating the product obtained in the step 2 by pretreated ODS column chromatography, performing gradient elution with methanol-water to obtain a plurality of elution parts, detecting by thin-layer chromatography, developing, and concentrating the developed elution parts under reduced pressure to dryness to obtain a concentrate for later use;

and 4, step 4: eluting the pretreated Sephadex LH-20 of the concentrate obtained in the step 3 with methanol, detecting by thin-layer chromatography, developing, and concentrating the developed elution parts under reduced pressure to dryness to obtain a concentrate for later use;

and 5: and (5) performing HPLC separation preparation on the concentrate obtained in the step (4), and performing isocratic elution by using acetonitrile-0.1% formic acid as a mobile phase to prepare a novel compound.

Further, 50% ethanol is extracted in a reflux manner in the step 1, and the dosage of the 50% ethanol is 8-16 times of that of the medicinal materials.

Further, the ethyl acetate mobile phase elution procedure used in the step 2 is isocratic elution; the mesh number of the silica gel is 100-200 meshes.

Further, the pretreatment process of ODS and Sephadex LH-20 in said

steps

3 and 4 is that methanol is soaked for 24 hours, loaded on the column, washed with methanol until no turbidity is formed in the dropping water, and then equilibrated with the initial mobile phase.

Further, the volume ratio of the methanol to the water used in the step 3 is 60: 40, 70: 30, 80: 20 and 90: 10; the filler particle size is 20 to 40 mu m.

Further, the methanol elution procedure used in step 4 is isocratic elution.

Further, the volume ratio of acetonitrile-0.1% formic acid used in said step 5 was 75: 25, and the compound retention time was 12.77 min.

The invention also provides application of the aryl compound separated from the purslane medicinal material by the method, and is characterized in that the application can be used for preparing anti-inflammatory and anti-tumor medicines.

Compared with the prior art, the invention has the beneficial effects.

The isolation and pharmacological activity studies of the purslane compounds in the invention are not reported in the journal of the prior paper; the invention provides a new compound from purslane and an extraction and separation method for the new compound, which successively adopts 50 percent ethanol reflux extraction, silica gel column chromatography, ODS medium-pressure column, Sephadex LH-20 and HPLC for separation, purification and preparation, so as to successfully extract and separate out the new compound, the method has five operation steps, the operation method is simple and rapid, the extraction and separation process mainly adopts water extraction and ethyl acetate elution, the process method is environment-friendly, and the purity of the compound separated by the method is higher and is more than 98 percent.

Drawings

FIG. 1 is a UV spectrum of a compound of the present invention.

FIG. 2 is an infrared spectrum of a compound of the present invention.

FIG. 3 is a high resolution mass spectrum of a compound of the present invention.

FIG. 4 is a drawing of a compound of the present invention¹H-NMR spectrum chart.

FIG. 5 is a drawing of a compound of the present invention¹³C-NMR spectrum chart.

FIG. 6 is a chart of HMBC spectra of the compounds of the present invention.

FIG. 7 is a HSQC spectrum of a compound of the present invention.

FIG. 8 is a drawing of a compound of the present invention¹H-¹H COSY spectrogram.

FIG. 9 is a ROESY spectrum of a compound of the present invention.

Detailed Description

The present invention will be described in detail with reference to specific examples.

Example 1.

The invention provides a compound with molecular formula of C₄₄H₄₂O, namely ((1)S,1'S,1''S,1'''S) - (oxybis (bezene-2, 1,3-triyl)) tetrakis (ethane-1,1-diyl)) tetrabenzene having the chemical formula:

。

the compound is named according to the structure ((1)S,1'S,1''S,1'''S) - (oxybis (bezene-2, 1,3-triyl)) tetrakis (ethane-1,1-diyl)) tetrabenzene, Table 1 being for this compound¹H-NMR of¹³C-NMR（DMSO-d ₆) The data of (1).

Table 1: nuclear magnetic data of the Compounds of the invention

。

Example 2 identification and derivation of the structure of a novel compound of the invention.

Yellowish oily substance, which is easily soluble in methanol, insoluble and slightly soluble in water. UV (MeOH) lambda_max：210nm、245nm、275nm，IR（KBr）ν_max：3041cm^-1、2861cm^-1、1641cm^-1、1612cm^-1、1565cm^-1And 1230cm^-1. HR-ESI (+) TOF-MS gives m/z: 587.3302[ M + H]⁺Has an excimer ion peak of 586.3236 molecular weight. Bonding of¹H-NMR，¹³C-NMR and DEPT data, presuming that the possible molecular formula of the compound is C₄₄H₄₂O, unsaturation degree is 24. In that¹H-NMR and¹³as can be seen in C-NMR, some signals are in¹H-NMR and¹³all are doubled in C-NMR. In the structural determination, each double peak is first regarded as a signal. In this way the origin is finally explained with respect to the double signal.

According to¹H-NMR, the four alkene hydrogen signal of the compound is delta_H6.74（1H，t，J=7.62）；δ_H6.79 （1H，t，J=7.62）；δ_H6.88（2H，d，J=7.62）；δ_H6.98（2H，d，J= 7.62), combined¹H-¹H-5 (. delta.) of the H COSY spectrum_H6.74) are related to H-4 and H-6, respectively, indicating the presence of a1, 2, 3-trisubstituted benzene ring in the compound. HMBC spectral displayH-5 is associated with C-1, C-3, H-6 with C-2, C-1', H-4 with C-2, C-1' ', H-1' with C-6, C-2 and H-1' ' ' with C-4 and C-2, indicating that C-1 and C-3 are linked to C-1' and C-1' ' ' respectively.¹H-¹H COSY shows a correlation from H-1 'to H-2', H-1'' 'to H-2' '', and HMBC shows a correlation from H-2 'to C-1' 'and H-1' to C-2, C-6, C-2'', C-6 ''; h-2'' 'associated with C-1' '' 'and H-1' '' associated with C-2, C-4, C-2'' ', C-6' '', confirming that there are two ethylbenzene s at C-1 and C-3, respectively. And related to HMBC from H-3 ' to C-5 ', C-1 '; h-5' and C-3', C-1 '; h-4' and C-2', C-6 '; h-2' and C-1', C-4 '; h-6' is related to C-1', C-4', respectively, further demonstrating a mono-substituted benzene ring on C-1', as well as C-1' ' '. It is reasonable to attach oxygen atoms based on the chemical shift of C-2 (delta 150.90). Because some signals are in¹H-NMR and¹³all are doubled in C-NMR, and it can be assumed that C-2 is attached to the same structure through oxygen. And the molecular ion peak of the structure is found in the mass spectrogram. From the above information, the novel compounds can be identified as having the above structure.

The invention also provides an extraction and separation method of the novel compound, which comprises the following specific steps:

step 1: weighing 250kg of dry purslane medicinal material, performing reflux extraction by adopting 50% ethanol, wherein the dosage of the 50% ethanol is 10 times of that of the medicinal material, performing decoction extraction twice, decocting for 2 hours each time, filtering water extracts, combining filtrates, heating and concentrating, and cooling to room temperature to obtain liquid medicine for later use;

step 2: evaporating the liquid medicine obtained in the step 1 to dryness, performing chromatographic separation by using a silica gel column, and isocratically eluting by using ethyl acetate (115L), wherein the silica gel is 100-200 meshes, the ethyl acetate is recovered to an extract at the temperature of more than room temperature and under reduced pressure of less than 40 ℃ to obtain an ethyl acetate extract;

and step 3: separating the product obtained in step 2 by pretreated ODS medium-pressure column chromatography, wherein the filler particle size is 20-40 μm, performing gradient elution (pressurizing to make flow rate 1mL/min, and temperature room temperature) with methanol-water (60: 40, 70: 30, 80: 20, and 90: 10, v/v) to obtain 16 parts (gradient elution is performed to obtain 16 bottles, each bottle is 100 mL), detecting by thin-layer chromatography, developing, and concentrating 70% and 80% parts at 50 deg.C under reduced pressure to dry for use. The ODS pretreatment process comprises the steps of soaking in methanol for 24 hours, loading on a column, washing with methanol until no turbidity exists in dropping water, and balancing with an initial mobile phase;

and 4, step 4: subjecting the fraction obtained in step 3 to Sephadex LH-20 column chromatography, isocratic eluting with methanol to obtain 26 fractions (i.e. gradient eluting to obtain 26 bottles, 50mL each), detecting by thin layer chromatography, developing, and concentrating the fractions 13 and 14 at 50 deg.C under reduced pressure to dryness. The pretreatment process of the Sephadex LH-20 comprises the steps of soaking for 24 hours in methanol, loading on a column, washing with the methanol until no turbidity exists in dropwise added water, and balancing with an initial mobile phase;

and 5: separating and preparing the chromogenic site obtained in the step 4 by HPLC, taking acetonitrile and 0.1% formic acid with the volume ratio of 75: 25 as a mobile phase, detecting the wavelength of 210nm and 280nm, and separating and preparing to obtain the novel compound, wherein the purity of the novel compound is more than 98% by a normalization method.

Example 3 anti-inflammatory action of the novel compounds of the present invention.

1 main material.

1.1 drugs and reagents: the new compounds used in the experiments were prepared by the above method, with a purity of over 98%, precisely weighed, and diluted with DMSO to the solutions required for the following dose groups. DMEM high-glucose medium, fetal bovine serum (Hyclone, usa); penicillin, streptomycin (Hangzhou Sijiqing Co.); LPS (Sigma, usa); IL-6, TNF-alpha, PGE₂ELISA kit of (A) (Cayman, USA); cell lysate, Griess reagent (bi yun tian biotechnology limited).

1.2 cell lines: RAW264.7 macrophages (us ATCC cell bank).

1.3 grouping: the test group was divided into a control group, an LPS group and an experimental group.

2 experimental methods.

2.1 cell culture, DMEM high sugar medium, with addition of l0% fetal bovine serum, l% antibiotics (100U/mL penicillin and 100. mu.g/mL streptomycin), CO at 37.5 deg.C₂Culturing in an incubator.

2.2 MTT colorimetric assayDetermining cell activity, inoculating RAW264.7 macrophage in logarithmic growth phase into 96-well culture plate with cell density of 1 × 10⁴one/mL, 100. mu.L per well, temperature 37 ℃, 5% CO₂After overnight culture under the condition, the experimental group is added with the novel compound (1 mu M-50 mu M) with different concentrations, LPS with the final concentration of 1 mu g/mL is respectively added into the LPS group and the experimental group after 1h incubation, a zero-adjusting group (culture solution containing DMSO solvent) is additionally arranged, each group is provided with 3 multiple holes, and the influence on cells after the addition of the medicament is inspected. After culturing the above groups of cells for 24 hours, 20. mu.L of MTT with a concentration of 5mg/mL was added to each well of cells at 37 ℃ with 5% CO₂After incubation for 4h, terminating the culture, absorbing the liquid in the wells, adding 100 μ L of dimethyl sulfoxide (DMSO) into each well, oscillating for 10min to dissolve the intracellular crystal, and measuring the light absorption value of each well at 570nm wavelength of an enzyme-labeling instrument.

2.3 measurement of inflammatory factors IL-6, TNF-alpha and inflammatory mediators PGE by ELISA₂: RAW264.7 macrophages in logarithmic growth phase were seeded in 24-well culture plates at a cell density of 1X 10⁵one/mL, 1mL per well, temperature 37 ℃, 5% CO₂After incubation overnight under these conditions, the experimental groups were incubated with the novel compounds of the present invention (1. mu.M-20. mu.M) for 1h, LPS (final concentration of 1. mu.g/mL) was added to each well, and incubated for 24h, with 3 wells per treatment. ELISA method for measuring IL-6, TNF-alpha and PGE secreted by RAW264.7 macrophage after treatment of purslane-derived novel compound₂The content of (b).

3, experimental results.

The experimental result shows that the novel compound containing the peroxy bond has no influence on the proliferation of macrophage RAW264.7 induced by LPS, and is safe and nontoxic; and can effectively inhibit excessive inflammatory cytokines IL-6, TNF-alpha and inflammatory mediators NO and PGE generated by macrophage RAW264.7 induced by LPS₂And is concentration dependent.

The results of the cell relative survival experiments are shown in table 2.

Table 2: effect of the invention on the relative survival of RAW264.7 macrophages

Note:^*P<0.05 compared with the control group (significant difference in the high concentration group).

ELISA method for measuring IL-6, TNF-alpha and PGE (inflammatory mediator)₂The results are shown in Table 4.

Table 3: the invention relates to IL-6, TNF-alpha and PGE secreted by RAW264.7 cells induced by LPS₂Influence of the amount

Note: the mean value. + -. the standard deviation of the mean,n=3，^*P<0.05 compared with the control group,^#P<0.05 compared to the LPS group.

EXAMPLE 4 antitumor Effect of the novel Compound of the present invention

1 main material.

1.1 drugs and reagents: the new compounds used in the experiments were prepared by the above method, with a purity greater than 98%, accurately weighed, and diluted with DMSO to the solutions required for the following dose groups. DMEM high-glucose medium, fetal bovine serum (Hyclone, usa); penicillin and streptomycin (Hangzhou Sijiqing Co., Ltd.).

1.2 cell lines: human colon cancer cell Caco-2, human breast cancer cell MCF-7, human gastric cancer cell BGC-823, human lung adenocarcinoma cell SPC-A1, human liver cancer cell BEL-7402, human cervical cancer cell Hela-229, ovarian cancer cell Ho-8910, and human oral epidermoid carcinoma cell KB (Shanghai cell Bank of China academy of sciences).

1.3 grouping: divided into a control group, an experimental group and a zero-adjustment group (culture solution containing DMSO solvent).

2 experimental methods.

2.1 cell culture, DMEM high sugar medium, added with 0% fetal bovine serum, l% antibiotics (100U/mL penicillin and 100. mu.g/mL streptomycin), placed at 37 ℃ and 5% CO₂Culturing in an incubator.

2.2 MTI method for detecting cell proliferation, inoculating cells in logarithmic growth phase into 96-well culture plate, and keeping cells denseDegree of 1X 10⁴one/mL, 100. mu.L per well, temperature 37 ℃, 5% CO₂After overnight culture under the conditions, the experimental groups were added with the novel compounds of the present invention at different concentrations, each group was provided with 3 multiple wells, and after adding the drug, the mixture was placed at 37 ℃ and 5% CO₂Culturing in an incubator for 48 h. The drug-containing culture solution is sucked up, 100mL of serum-free culture solution and MTT (final mass concentration is 5mg/mL) are added in a volume ratio of 4: 1, incubation is continued for 4h, after supernatant is carefully sucked up, 150 mu L of DMSO is added into each hole, the mixture is placed on a vibrator to be vibrated so as to completely dissolve crystals (5 min), and an enzyme-labeling instrument detects the absorbance (A) value of each hole at the wavelength of 570 nm. Then, the inhibition rate of each concentration of compound on cell growth is calculated, and the inhibition rate formula is as follows: cell growth inhibition rate = (1-A)_{Medicine feeding hole}／A_{Control well}) X 100%, processing data with SPSS software, plotting inhibition rate against drug concentration, and calculating IC₅₀The value is obtained.

3, experimental results.

Experimental results show that the novel compound has an inhibition effect on proliferation of human colon cancer cells Caco-2, human breast cancer cells MCF-7, human gastric cancer cells BGC-823, human lung adenocarcinoma cells SPC-A1, human liver cancer cells BEL-7402, human cervical cancer cells Hela-229, ovarian cancer cells Ho-8910 and human oral epidermoid cancer cells KB, and the inhibition rate is obviously increased along with the increase of the drug concentration, namely the inhibition rate is concentration dependent. The novel compound of the invention is used for treating the eight tumor cells IC₅₀The values are shown in Table 5.

Table 4: effect of the present invention on the Effect of Each cell line

。

In conclusion, the invention provides the special compound and the extraction and separation method thereof, the new compound is successfully separated and obtained by sequentially adopting 50% ethanol reflux extraction, silica gel column chromatography, ODS medium-pressure column, Sephadex LH-20 column chromatography and HPLC separation and purification, the method is simple, convenient, rapid and environment-friendly, the purity of the compound separated and obtained by the method is higher, and the obtained compound has unique chemical structure, is extracted from the common traditional Chinese medicine purslane and has the anti-tumor and anti-inflammatory effects, so the special compound, the salt and the derivative thereof can be used as a natural product to develop new traditional Chinese medicines, and have wide prospects.

Claims

1. An aryl compound isolated from a purslane herb, wherein the compound has the formula: c₄₄H₄₂O and is named according to the structure ((1)S,1'S,1''S,1'''S) - (oxybis (bezene-2, 1,3-triyl)) tetrakis (ethane-1,1-diyl)) tetrabenzene having the chemical formula

。

2. The method for extracting and separating an aryl compound according to claim 1, wherein the method comprises the following specific steps:

step 1: extracting herba Portulacae dry medicinal materials with 40-60% ethanol under reflux, mixing filtrates, directly heating and concentrating, and cooling to room temperature to obtain medicinal liquid;

and 5: and (4) carrying out HPLC separation preparation on the concentrate obtained in the step (4), and carrying out isocratic elution by using acetonitrile-0.1% formic acid as a mobile phase to prepare a novel compound.

3. The extraction and separation method of claim 2, wherein the ethanol with a certain concentration in the step 1 is extracted by reflux, and the dosage of the ethanol is 8 to 16 times of that of the medicinal materials.

4. The extraction separation method according to claim 2, wherein the ethyl acetate mobile phase elution procedure used in the step 2 is isocratic elution; the mesh number of the silica gel is 100-200 meshes.

5. The extraction separation method according to claim 2, wherein the pretreatment process of the ODS column in step 3 and the Sephadex LH-20 column in step 4 is soaking in methanol for 24 hours, loading on the column, washing with methanol until the dropping water is free from turbidity, and then equilibrating with an initial mobile phase.

6. The extraction separation method according to claim 2, wherein the volume ratio of methanol to water used in the step 3 is 60: 40, 70: 30, 80: 20, 90: 10; the filler particle size is 20 to 40 mu m.

7. The extraction separation method according to claim 2, wherein the methanol elution procedure used in step 4 is isocratic elution.

8. The extraction separation method of claim 2, wherein the volume ratio of acetonitrile-0.1% formic acid used in step 5 is 75: 25, and the retention time of the compound is 12.77 min.

9. Use of an aryl compound according to claim 1 for the preparation of an anti-inflammatory, anti-tumour agent.